(Nasdaq: MIRM) today announced that on 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

A groundbreaking discovery about how plants defend themselves against environmental threats could transform the way we grow food, per Phys.org. Researchers have identified a previously unknown ...

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

It is expressed in several tissues. 14 Thus, it is no surprise that MUL shares features with other peroxisomal disorders. These include growth failure, facial dysmorphism with midface hypoplasia, ...

Understanding the molecular mechanisms of insulin resistance remains a major medical challenge of the twenty-first century. Over the last half-century, many hypotheses have been proposed to ...

After hours: February 12 at 4:20:00 PM EST Loading Chart for MIRM ...

Background Schaaf-Yang syndrome (SYS) is caused by truncating mutations in MAGEL2, mapping to the Prader-Willi region (15q11-q13), with an observed phenotype partially overlapping that of Prader-Willi ...

Hepatic fibrosis is the final pathway of several chronic liver diseases, which is characterized by the accumulation of extracellular matrix due to chronic hepatocyte damage. Activation of hepatic ...